Medivir AB 

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phase II studies for treating mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a cathepsin K inhibitor that has completed Phase II studies to treat osteoarthritis; and fostroxacitabine bralpamide (fostrox), a liver-targeted treatment that has completed Phase IIa to treat liver cancer. In addition, the company develops Birinapant that has completed Phase I study for the treatment of solid tumors; VBX-1000 that has completed proof-of-concept clinical study to treat canine periodontitis; USP-1/TNG348, a preclinical project for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers; USP-7, a pre-clinical project to treat cancer; and MBLI/MET-X, a pre-clinical project for the treatment of infection. It has a collaboration and supply agreement with Eisai; and licensing agreements with IGM Biosciences, Tango Therapeutics, and Ubiquigent. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.